Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$51.4K Sell
146
-104
-42% -$37.1K ﹤0.01% 359
2025
Q4
$81.9K Buy
250
+115
+85% +$36.5K 0.01% 291
2025
Q3
$38.1K Hold
135
﹤0.01% 356
2025
Q2
$37.7K Sell
135
-368
-73% -$104K ﹤0.01% 356
2025
Q1
$157K Sell
503
-132
-21% -$39K 0.02% 221
2024
Q4
$166K Sell
635
-526
-45% -$156K 0.02% 207
2024
Q3
$330K Buy
1,161
+518
+81% +$169K 0.05% 135
2024
Q2
$201K Sell
643
-524
-45% -$154K 0.03% 154
2024
Q1
$332K Sell
1,167
-2,664
-70% -$780K 0.05% 136
2023
Q4
$1.1M Sell
3,831
-14
-0.4% -$3.81K 0.18% 83
2023
Q3
$1.03M Buy
3,845
+26
+0.7% +$6.49K 0.19% 83
2023
Q2
$848K Buy
+3,819
New +$886K 0.15% 92

Other funds holding AMGN

Nemes Rush Group's AMGN Position: Q1 2026 in Review

Nemes Rush Group reduced its Amgen (AMGN) stake by 42% in Q1 2026, selling an estimated $37.1K and leaving 146 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Nemes Rush Group first reported a position in AMGN in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.1M in Q4 2023. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Nemes Rush Group held 146 shares of Amgen worth $51.4K as of Q1 2026.
  • Nemes Rush Group sold 104 Amgen shares in Q1 2026, an estimated $37.1K.
  • Amgen made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #359 holding.
  • Nemes Rush Group first reported a position in Amgen in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Amgen position peaked at $1.1M in Q4 2023.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.